BG102235A - Method for the reduction of the quantity of exogenous insulin applied to patients suffering from insulin-independent diabetes melitus - Google Patents

Method for the reduction of the quantity of exogenous insulin applied to patients suffering from insulin-independent diabetes melitus

Info

Publication number
BG102235A
BG102235A BG102235A BG10223598A BG102235A BG 102235 A BG102235 A BG 102235A BG 102235 A BG102235 A BG 102235A BG 10223598 A BG10223598 A BG 10223598A BG 102235 A BG102235 A BG 102235A
Authority
BG
Bulgaria
Prior art keywords
insulin
reduction
patients suffering
independent diabetes
diabetes melitus
Prior art date
Application number
BG102235A
Other languages
Bulgarian (bg)
English (en)
Inventor
Randall WHITCOMB
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of BG102235A publication Critical patent/BG102235A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG102235A 1995-08-10 1998-02-05 Method for the reduction of the quantity of exogenous insulin applied to patients suffering from insulin-independent diabetes melitus BG102235A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US209895P 1995-08-10 1995-08-10
PCT/US1996/012430 WO1997005875A2 (en) 1995-08-10 1996-07-29 A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus

Publications (1)

Publication Number Publication Date
BG102235A true BG102235A (en) 1998-09-30

Family

ID=21699238

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102235A BG102235A (en) 1995-08-10 1998-02-05 Method for the reduction of the quantity of exogenous insulin applied to patients suffering from insulin-independent diabetes melitus

Country Status (15)

Country Link
EP (1) EP0851757A2 (cs)
JP (1) JPH11510508A (cs)
KR (1) KR19990036290A (cs)
CN (1) CN1192683A (cs)
AU (1) AU724989B2 (cs)
BG (1) BG102235A (cs)
CA (1) CA2221241A1 (cs)
CZ (1) CZ32998A3 (cs)
EA (1) EA199800177A1 (cs)
HU (1) HUP9802543A2 (cs)
IL (1) IL122191A0 (cs)
NO (1) NO980556L (cs)
NZ (1) NZ313874A (cs)
SK (1) SK16498A3 (cs)
WO (1) WO1997005875A2 (cs)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
GB9712866D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
GB2335597A (en) * 1998-03-27 1999-09-29 Glaxo Group Ltd Stereoisomers of Troglitazone in the Treatment of Diabetes
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
EP1087963B1 (en) 1998-06-19 2004-08-25 Chiron Corporation Inhibitors of glycogen synthase kinase 3
FR2838968A1 (fr) * 2002-04-30 2003-10-31 Lipha Association d'insuline et d'un derive de thiazolidinedione et son utilisation pour traiter le diabete

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
JPH11510508A (ja) 1999-09-14
NO980556D0 (no) 1998-02-09
SK16498A3 (en) 1999-03-12
WO1997005875A3 (en) 1997-03-27
CN1192683A (zh) 1998-09-09
NO980556L (no) 1998-02-09
CZ32998A3 (cs) 1998-10-14
HUP9802543A2 (hu) 1999-07-28
WO1997005875A2 (en) 1997-02-20
NZ313874A (en) 2000-09-29
CA2221241A1 (en) 1997-02-20
AU724989B2 (en) 2000-10-05
IL122191A0 (en) 1998-04-05
KR19990036290A (ko) 1999-05-25
AU6641196A (en) 1997-03-05
EP0851757A2 (en) 1998-07-08
EA199800177A1 (ru) 1998-10-29

Similar Documents

Publication Publication Date Title
EP0420603A3 (en) Pressure regulator and its method of assembly
AU4978896A (en) Improved breast pump assembly and method of using same
EP0598252A3 (en) Diaphragm controlled pressure regulators and manufacturing processes.
AU4237896A (en) Method and intermediates for the synthesis of korupensamines
AU6859196A (en) Process for decreasing the acid content and corrosivity of crudes
AU6599798A (en) Blood pump device and method of producing
AU7236596A (en) Transdermal administration of ropinirole and analogs thereof
AU4617696A (en) Transformer and method of assembly
IL117446A0 (en) Esters and amides of disubstituted 1,4-piperidine
AU3977195A (en) Securing of reinforcing strips
AU5326496A (en) Acoustic imaging catheter and method of operation
AU7225396A (en) Method and system for determination of the pressure-volume relationship of the heart
GB2303240B (en) Structure and operation method of LCD
AU7680096A (en) Combinations of dp and fp type prostaglandins for lowering iop
BG102235A (en) Method for the reduction of the quantity of exogenous insulin applied to patients suffering from insulin-independent diabetes melitus
AU3822589A (en) Method and apparatus for the assembly of friction components
ZA947783B (en) Method of treating depressed reticuloendothelial system function
AU2453597A (en) Metal casket and method of making the same
EP0834013A4 (en) FUEL PUMP AND METHOD FOR THEIR OPERATION
AU5544994A (en) Use of 17alpha-dihydroequilenin for lowering cholesterol
AU572261B2 (en) Process for transforming teicoplanin factor a2 component 1 into teicoplanin factor a2 component
AU6299596A (en) Prevention of a disease having the characteristics of diabetes
AU7718796A (en) 4-hydroxycoumarin-3-carboxamides for the treatment of diabetes mellitus
AU6031696A (en) Furanoeremophilane and eremophilanolide sesquiterpenes for t reatment of diabetes
DE69620602D1 (de) Gewebeladesystem für implantierbare biologische vorrichtungen